Company records / cybrexa.com

Cybrexa Therapeutics

Cybrexa Therapeutics (cybrexa.com): 1 change recorded in its website history since June 2017. Homepage last checked 5 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

HeadlineBetween 18 January 2018 and 7 January 2019
BeforeCybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvi…
Aftertargeted intracellular delivery
Observed on the company’s website; business claims are not independently verified.
earlier archived page later archived page Link to observation

First recorded website

Observed 19 June 2017

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

Cybrexa Therapeutics | Changing the paradigm of cancer drug delivery.

Changing the paradigm of cancer drug delivery.

archived page Link to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

January 2019 – November 2026 · 11 captures · latest observed messagingtargeted intracellular delivery
This wording observed 5 November 2026.
current websiteHistorical capture not publicly available
Inspect 11 captures in this group
- 7 January 2019 · targeted intracellular delivery archived page
- 21 February 2020 · targeted intracellular delivery archived page
- 25 January 2021 · targeted intracellular delivery archived page
- 11 January 2022 · targeted intracellular delivery archived page
- 5 February 2023 · targeted intracellular delivery archived page
- 4 January 2024 · targeted intracellular delivery archived page
- 14 January 2025 · targeted intracellular delivery archived page
- 3 August 2025 · targeted intracellular delivery archived page
- 12 February 2026 · targeted intracellular delivery archived page
- 18 June 2026 · targeted intracellular delivery archived page
- 5 November 2026 · targeted intracellular delivery current websiteHistorical capture not publicly available
Seen January 2018 · 1 captureCybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.
Cybrexa Therapeutics is changing the paradigm of cancer drug delivery with tumor-localizing peptide technology. We are located near Yale in New Haven, CT.
This wording observed 18 January 2018.
archived page
Seen June 2017 · 1 captureCybrexa Therapeutics | Changing the paradigm of cancer drug delivery.
Changing the paradigm of cancer drug delivery.
This wording observed 19 June 2017.
archived page

Cite this record

StartupHistory, “Cybrexa Therapeutics” company record, https://startuphistory.org/c/cybrexa.com

Machine-readable: /c/cybrexa.com.json. How changes are found: method.